Mohammad Dada, MD
Psychiatry · Rocky Hill, CTNPI 1457307043
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.1% of the total across 622 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 24.8% of the total. Reporting peaked in 2023 at $3,998 and has fallen 55.5% since, to $1,779 in 2025. Among psychiatry clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 622 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Neuronetics, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$906
- Vanda Pharmaceuticals Inc.$852
- Lundbeck LLC$795
- Takeda Pharmaceuticals U.S.A., Inc.$769
- plus $4K from 22 others
What the payments were for
- Travel & lodging$7657%
- Food & beverage$10,61593%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 231 | $2,825 |
| Neuronetics, Inc. | 2 | $1,314 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 59 | $906 |
| Vanda Pharmaceuticals Inc. | 45 | $852 |
| Lundbeck LLC | 52 | $795 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $769 |
| Teva Pharmaceuticals USA, Inc. | 31 | $621 |
| Otsuka America Pharmaceutical, Inc. | 30 | $500 |
| Alkermes, Inc. | 28 | $496 |
| Johnson & Johnson | 18 | $472 |
| Neurocrine Biosciences, Inc. | 13 | $333 |
| Axsome Therapeutics, Inc. | 14 | $314 |
| E.r. Squibb & Sons, L.L.C. | 9 | $239 |
| Corium, LLC | 6 | $143 |
| Idorsia Pharmaceuticals US Inc | 6 | $108 |
| Supernus Pharmaceuticals, Inc. | 5 | $100 |
| Acadia Pharmaceuticals Inc | 5 | $96 |
| Eisai Inc. | 5 | $89 |
| Indivior Inc. | 5 | $86 |
| Shire North American Group Inc | 3 | $71 |
| Almatica Pharma LLC | 3 | $69 |
| Bausch Health US, LLC | 3 | $56 |
| Luye Pharma (USA) Ltd. | 2 | $38 |
| Avanir Pharmaceuticals, Inc. | 2 | $34 |
| Orexo US, Inc. | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Noven Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$1,314
- SPRAVATO$168
How this compares
$11,407 in reported general payments places this provider in the 90th percentile of 644 psychiatry providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 33 | $58,359 |
| TrintellixVortioxetine Hydrobromide | 20 | $16,272 |
| BelsomraSuvorexant | 16 | $10,824 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $9,542 |
| Vilazodone Hcl | 95 | $7,342 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 64 | $7,155 |
| Aripiprazole | 149 | $4,694 |
| Quetiapine Fumarate | 208 | $4,069 |
| Duloxetine Hcl | 232 | $3,667 |
| Perphenazine | 35 | $3,533 |
| Clonazepam | 305 | $3,266 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 46 | $2,802 |
| Lurasidone Hcl | 30 | $2,623 |
| Bupropion XlBupropion Hcl | 106 | $2,593 |
| Buspirone Hcl | 136 | $2,136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $500 | $58,35933 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $769 | $16,27220 claims |
| Indivior Inc.Suboxone | $86 | $9,54212 claims |
| Almatica Pharma LLCSertraline Hcl | $69 | $881115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 644 psychiatry providers in Connecticut.
Other psychiatry in Rocky Hill
- Vladimir CoricNew Haven$133.7M
- Donald AmmermanDanbury$1.5M
- Joseph GoldbergNew Canaan$914K
- Lisa HardingMilford$608K
- Tarique PereraDanbury$383K
- John GelinasDanbury$364K
- Irene AbramovichWest Hartford$352K
- Robert BermanNew Haven$126K
- John KrystalWest Haven$122K
- David MatuskeyFarmington$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.